Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | MAGNOLIA trial: zanubrutinib for MZL

Stephen Opat, FRACP, FRCPA, MBBS, Monash University, Melbourne, Australia, shares the findings of the Phase II MAGNOLIA trial (NCT03846427) evaluating the safety and efficacy of a next-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib, in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL). After 10 months, zanubrutinib has been shown to be efficacious, with a 74% overall response rate (ORR) and rates expected to increase with longer follow-up. The clinical benefits seen with zanubrutinib use extended to various MZL subtypes including extranodal, nodal, and splenic. A favorable safety profile was observed, with the most common adverse event being neutropenia. Follow-up is ongoing to improve understanding of the durability of responses. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Research payments to institution: Beigene